Metabolism of 2-phenylethylamine to phenylacetic acid, via the intermediate phenylacetaldehyde, by freshly prepared and cryopreserved guinea pig liver slices

In Vivo

Volumn 18, Issue 6, 2004, Pages 779-786

  Panoutsopoulos, Georgios I ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

2 phenylethylamine; Aldehyde dehydrogenase; Aldehyde oxidase; Allopurinol; Biogenic amines; Disulfiram; Isovanillin; Liver slices; Phenylacetaldehyde; Xanthine oxidase

Indexed keywords

ACETALDEHYDE; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE INHIBITOR; ALDEHYDE OXIDASE; ALLOPURINOL; DISULFIRAM; ISOVANILLIN; PHENETHYLAMINE; PHENYLACETIC ACID; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; GUINEA PIG; LIVER PARENCHYMA; METABOLIC INHIBITION; METABOLISM; NONHUMAN; OXIDATION; TISSUE SLICE; TOXICOKINETICS;

EID: 11944259121     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Henry DP, Russell WL, Clemens JA and Plebus LA: Phenylethylamine and p-tyramine in the extracellular space of the rat brain: quantification using a new radioenzymatic assay and in situ microdialysis. In: Trace Amines: Comparative and Clinical Neurobiology (Boulton AA, Juorio AV and Downer RGH, eds). Humana Press, Clifton, NJ, 1988, pp 239-250.
2. Paterson IA, Jurio AV and Boulton AA: 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system. J Neurochem 55: 1827-1837, 1990.
3. Dyck LE, Yang CR and Boulton AA: The biosynthesis of ptyramine, m-tyramine, and β-phenylethylamine by rat striatal slices. J Neurochem Res 10: 211-220, 1983.
4. Barroso N and Rodriguez M: Action β-phenylethylamine and related amines on nigrostriatal dopamine neurotransmission. Eur J Pharmacol 297: 195-203, 1996.
5. Berry MD, Scarr E, Zhu M-Y, Paterson IA and Juorio AV: The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine. Br J Pharmacol 113: 1159-1166, 1994.
6. Paterson IA, Jurio AV and Boulton AA: Possible mechanism of action of deprenyl in parkinsonism. Lancet 336: 183, 1990.
7. Bergman J, Yasar S and Winger G: Psychomotor stimulant effects of β-phenylethylamine in monkeys-treated with MAO-B inhibitors. Psychopharmacology 159: 21-30, 2001.
8. Martin VT and Behbehani MM: Headache: toward a rational understanding of migraine trigger factors. Med Clin N Am 85: 1-20, 2001.
9. Millichap JG and Yee MM: The diet factor in pediatric and adolescent migraine. Pediatr Neurol 28: 9-15, 2003.
10. Sandler M, Youdim MB and Hanington E: A phenylethylamine oxidizing defect in migraine. Nature 250: 335-337, 1974.
11. Quian M and Reineccius G: Identification of aroma compounds in Parmigiamo-Reggiano cheese by gas chromatography/olfactometry. J Dairy Sci 85: 1362-1369, 2002.
12. Hyotylainen T, Savola N, Lehtonen P and Riekkola ML: Determination of biogenic amines in wine by multidimensional liquid chromatography with online derivatisation. Analyst 126: 2124-2127, 2001.
13. Aznar M, Lopez R, Cacho J and Ferreira V: Prediction of aged red wine aroma properties from aroma chemical composition: partial least squares regression models. J Agric Food Chem 51: 2700-2707, 2003.
14. Salach JI: Monoamine oxidase from beef liver mitochondria: simplified isolation procedure, properties, and determination of its cysteinyl flavin aoutent. Arch Biochem Biophys 192: 128-137, 1979.
15. Wouters J: Structural aspects of monoamine oxidase and its reversible inhibition. Curr Med Chem 5: 137-162, 1998.
16. Feldman RI and Weiner H: Horse liver aldehyde dehydrogenase. I. Purification and characterization. J Biol Biochem 247: 260-266, 1972.
17. Panoutsopoulos GI, Kouretas D, Gounaris EG and Beedham C: Metabolism of 2-phenylethylamine and phenylacetaldehyde by precision-cut guinea pig fresh liver slices. Eur J Drug Metab Pharmacokin 29: 111-118, 2004.
18. De Kanter R, Olinga P, De Jager MH, Merema MT, Meijer DKF and Groothius GMM: Organ slices as an in vitro test system for drug metabolism in human liver, lung and kidney. Toxicol In Vitro 13: 737-744, 1999.
19. Lerche-Langrand C and Toutain HJ: Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. Toxicology 153: 221-253, 2000.
20. Smith PF, Krack G, McKee RL, Johnson DG, Gandolfi AJ, Hruby VJ, Krumdieck CL and Brendel K: Maintenance of adult rat liver slices in dynamic organ culture. In Vitro Cell Dev Biol 22: 706-712, 1986.
21. Parrish AR, Gandolfi AJ and Brendel K: Precision-cut liver slices: applications in pharmacology and toxicology. Life Sci 21: 1887-1901, 1995
22. De Kanter R, Olinga P, Hof I, De Jager M, Verwillegen WA, Slooff MJ, Koster HJ, Meijer DK and Groothuis GM: A rapid and simple method for cryopreservation of human liver slices. Xenobiotica 28: 225-234, 1998.
23. Day SH, Nicoll-Griffith DA and Silva JM: Cryopreservation of rat and human liver slices by rapid freezing. Cryobiology 38: 154-159, 1999.
24. De Graaf IAM and Koster HJ: Cryopreservation of precision-cut tissue slices for application in drug metabolism research. Toxicol In Vitro 17: 1-17, 2003.
25. Martignoni M, Monshouwer M, de Kanter R, Pezzetta D, Moscone A and Grossi P: Phase I and phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservation. Toxicol In Vitro 18: 121-128, 2004.
26. Panoutsopoulos GI and Beedham C: Kinetics and specificity of guinea pig liver aldehyde oxidase and bovine milk xanthine oxidase towards substituted benzaldehydes. Acta Biochim Polon 51: 649-663, 2004.
27. Panoutsopoulos GI, Kouretas D and Beedham C: Contribution of aldehyde oxidase, xanthine oxidase and aldehyde dehydrogenase on the oxidation of aromatic aldehydes. Chem Res Toxicol 17: 1368-1376, 2004.
28. Peterson GM, Boyle RR, Francis HW, Oliver NWJ, Paterson J, von Witt RJ and Taylor GR: Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy. Eur J Pharmacol 39 419-421, 1990.
29. Deitrich RA and Erwin VG: Mechanism of the inhibition of aldehyde dehydrogenase in vivo by disulfiram and diethyldithiocarbamate. Mol Pharmacol 7: 301-307, 1971.
30. Lipsky JJ, Shen ML and Naylor S: Overview-In vitro inhibition of aldehyde dehydrogenase by disulfiram and metabolites. Chem-Biol Interact 130-132: 81-91, 2001.
31. Beedham C, Peet CF, Panoutsopoulos GI, Carter H and Smith JA: Role of aldehyde oxidase in biogenic amine metabolism. Prog Brain Res 106: 345-353, 1995.
32. Tweedie DJ, Fernandez D, Spearman ME, Feldhoff RC and Prough RA: Metabolism of azoxy derivatives of procarbazine by aldehyde dehydrogenase and xanthine oxidase. Drug Metab Disp 19: 793-803, 1991.
33. Panoutsopoulos GI and Beedham C: Enzymatic oxidation of vanillin, isovanillin and protocatechuic aldehyde with freshly prepared guinea pig liver slices. Cell Physiol Biochem 15: in press, 2005.
34. 2-dependent activity. Biochem J 207: 341-346, 1982.
35. Della Corte E and Stripe F: The regulation of rat liver xanthine oxidase: Involvement of thiol groups in the conversion of the enzyme activity from dehydrogenase (type D) into oxidase (type O) and purification of the enzyme. Biochem J 126: 739-745, 1972.
36. 2-dependent (type O) forms of the rat liver xanthine dehydrogenase. Arch Biochem Biophys 172: 354-364, 1976.
37. Pietruszco R: In: Biochemistry and Physiology of Substance Abuse. (Watson RR, ed) CRC Press, Boca Raton, FL, 1989, Vol. 1, pp 89-127.
38. Klyosov AA: Kinetics and specificity of human liver aldehyde dehydrogenases toward aliphatic, aromatic, and fused polycyclic aldehydes. Biochemistry 35: 4457-4467, 1996.
39. Weiner H and Ardelt B: Distribution and properties of aldehyde dehydrogenase in regions of rat brain. J Neurochem 42 109-115, 1984.
40. Panoutsopoulos GI, Kouretas D, Gounaris EG and Beedham C: Enzymatic oxidation of 2-phenylethylamine to phenylacetic acid and 2-phenylethanol with special reference to the metabolism of its intermediate phenylacetaldehyde. Basic Clin Pharmacol Toxicol 95: in press, 2004.
41. Sipes IG, Fisher RL, Smith PF, Stine ER, Gandolfi AJ and Brendel K: A dynamic liver culture system: a tool for studying chemical biotransformation and toxicity. Arch Toxicol Suppl 11: 20-33, 1987.
42. Houslay MD and Tipton KF: A kinetic evaluation of monoamine oxidase activity in the rat liver mitochondrial outer membranes. Biochem J 139: 645-652, 1974.
43. Neff NH and Yang HYT: Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs. Life Sci 14: 2061-2074, 1974.
44. Egashira T, Ekstedt B and Oreland L: Inhibition by clorgyline and deprenyl of the different forms of monoamine oxidase in rat liver mitochondria. Biochem Pharmacol 25: 2583-2586, 1976.
45. Fuller RW, Warren BJ and Molloy BB: Selective inhibition of monoamine oxidase in rat brain mitochondria. Biochem Pharmacol 19: 2934-2936, 1970.
46. Fisher R, Putnam CW, Koep LJ, Sipes IG, Gandolfi AJ and Brendel K: Cryopreservation of pig and human liver slices. Cryobiology 28: 131-142, 1991.
47. Shaw S and Jayatilleke E: The role of cellular oxidases and catalytic iron in the pathogenesis of ethanol-induced liver injury. Life Sci 50: 2045-2052, 1992.
48. Critchley DJP, Rance DJ and Beedham C: Biotransformation of carbazeran in guinea pig: effect of hydralazine pre-treatment. Xenobiotica 24: 37-47, 1994.